CAR T Vision
CAR T Vision is an independent healthcare advocacy coalition launched in 2025 that unites hematologists, patient advocates, clinical societies, and industry to double, by 2030, the share of eligible blood cancer patients receiving CAR T-cell therapy, primarily in the US and Europe.
- Company typePrivate
- Founded2025
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What CAR T Vision does
CAR T Vision is an independent healthcare advocacy coalition launched in early 2025 with the stated goal of doubling, by 2030, the proportion of eligible patients treated with CAR T-cell therapy. The coalition is structured around an independent, multidisciplinary global Steering Committee of approximately 16 members spanning leading hematologists, patient advocacy organizations, clinical society leaders, technical experts, and health economists from North America and Europe. Its work focuses on three barrier categories — awareness and understanding of CAR T-cell therapy, treatment delivery capacity and referral pathways, and reimbursement/financing frameworks for one-time high-cost therapies — where currently only about two in ten eligible patients (and roughly 25-33% of LBCL patients in real-world studies) actually receive treatment.
The coalition's core outputs are publications and advocacy tools rather than technology products: an Inaugural Report (June 2025) outlining the Vision and priority areas; a Vision to Action Blueprint (June 2026) co-developed with more than 65 multidisciplinary experts, providing actionable interventions and progress indicators for the US and Europe; a companion Vision to Action Toolkit; and a Case Studies compendium. The site is operated by Incisive Health, a London-based healthcare communications consultancy serving as secretariat. The coalition does not sell products or services, does not have an API or software platform, and its outputs are distributed freely via the website and LinkedIn.
CAR T Vision is funded by industry supporters — Gilead and Kite (inaugural supporter), Autolus, and Legend Biotech — all of whom have commercial or development interests in CAR T-cell therapies. The coalition has secured endorsements from 12+ organizations including the Lymphoma Coalition, International Myeloma Foundation, Leukemia & Lymphoma Society, Foundation for the Accreditation of Cellular Therapy (FACT), Cell and Gene Therapy Catapult (CGT Catapult), American Society for Transplantation and Cellular Therapy (ASTCT), Association of Cancer Care Centers (ACCC), and Alliance for Regenerative Medicine (ARM). It is registered/operated in London, United Kingdom, with US terms governed by New York law, and operates across the US, UK, France, Germany, Italy, Spain, and Austria.
CAR T Vision firmographics
Firmographics- Name
- CAR T Vision
- Legal name
- Incisive Health
- Website
- https://cartvision.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CAR T Vision is an independent healthcare advocacy coalition launched in 2025 that unites hematologists, patient advocates, clinical societies, and industry to double, by 2030, the share of eligible blood cancer patients receiving CAR T-cell therapy, primarily in the US and Europe.
- Ownership category
- akta.pro rank
CAR T Vision industry classification
Industry- Product category
- Healthcare Advocacy Coalition Publications
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
Keywords
Where CAR T Vision is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
CAR T Vision business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Industry funding and support: CAR T Vision activities and outputs are led by an independent Steering Committee, made possible through funding from industry supporters Gilead and Kite (a Gilead company), Autolus, and Legend Biotech. Initial activities, including the development of the inaugural report, were funded by Gilead and Kite as the inaugural supporter.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
CAR T Vision product offering
Product offeringCore offering
CAR T Vision is an independent healthcare advocacy coalition that publishes expert-informed reports, blueprints, toolkits, and case studies to drive stakeholder action on expanding patient access to CAR T-cell therapy. It is led by a multidisciplinary global Steering Committee and operates without selling any commercial products; all publications are distributed for free via its website to align policymakers, payors, healthcare professionals, patient advocates, and industry around the goal of doubling the proportion of eligible patients treated by 2030.
Product overview
CAR T Vision is a coalition offering a portfolio of publications, blueprints, and educational resources rather than a unified software product. The core offerings include the CAR T Vision Inaugural Report (establishing goals and access barriers), the Vision to Action Blueprint (actionable interventions for stakeholders), the Vision to Action Toolkit (practical implementation guidance), and a Case Studies compendium (real-world examples). These publications work together to provide a comprehensive framework for advocacy and action to expand patient access to CAR T-cell therapy.
Differentiator
Problem solved
Functional benefit
Products and services
- CAR T Vision Inaugural Report Comprehensive report outlining the CAR T Vision, its goals, the access challenges it seeks to address, and priority areas for progress in expanding patient access to CAR T-cell therapy. Aimed at policymakers, payors, healthcare professionals, patient advocates, and industry stakeholders.
- Vision to Action Blueprint Expert-informed plan providing actionable interventions and real-world case studies to address barriers to CAR T-cell therapy access in the US and Europe, accompanied by progress measurement indicators. Aimed at country-level stakeholders across awareness, capacity, and financing dimensions.
- Vision to Action Toolkit Practical toolkit to help stakeholders identify priority actions, engage partners, and develop locally tailored solutions to increase patient access to CAR T-cell therapy. Companion resource to the Vision to Action Blueprint.
- Case Studies Collection of real-world examples demonstrating implementable solutions to address challenges in CAR T-cell therapy access across awareness, capacity, and financing areas. Available as free downloadable resources on the website.
Quantifiable outcome
- Doubling the proportion of eligible patients treated with CAR T-cell therapy by 2030 (from ~20% to ~40% of eligible patients)
- +6 more outcomes
Companies that use CAR T Vision
Customer profileSegments4 records
Ideal customer profiles4 records
CAR T Vision technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CAR T Vision partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered supporting and core.
- Advance Practitioner Society for Hematology and Oncology (APSHO)supportingAPSHO is one of 12+ organizations that has endorsed the CAR T Vision, indicating support for the coalition's goals and recommendations for improving patient access to CAR T-cell therapy.
- Alliance for Regenerative Medicine (ARM)supportingARM is an endorsing organization of the CAR T Vision, supporting the coalition's mission to expand equitable access to CAR T-cell therapy.
- Association of American Cancer Institutes (AACI)supportingAACI has endorsed the CAR T Vision and participated in coalition initiatives such as the RECUR initiative (with ASTCT and ACCC) for patient identification and referral.
- Association of Cancer Care Centers (ACCC)supportingACCC is an endorsing organization and has partnered on specific initiatives including the 'Bringing CAR T-cell Therapies to Community Oncology' initiative and the RECUR initiative for patient identification.
- Barts Cancer InstitutesupportingBarts Cancer Institute, Queen Mary University of London, has endorsed the CAR T Vision. Dr. John Gribben from Barts Cancer Institute serves on the Steering Committee.
- CancerCaresupportingCancerCare has endorsed the CAR T Vision, supporting the coalition's advocacy goals for improved patient access to CAR T-cell therapy.
- Cancer Support CommunitysupportingCancer Support Community has endorsed the CAR T Vision, contributing to the coalition's patient advocacy mission.
- Cell and Gene Therapy Catapult (CGT Catapult)supportingCGT Catapult has endorsed the CAR T Vision. Jacqueline Barry, Chief Clinical Officer of CGT Catapult, serves on the Steering Committee. CGT Catapult coordinates the ATTC network in the UK.
- Foundation for the Accreditation of Cellular Therapy (FACT)supportingFACT has endorsed the CAR T Vision. David Schmahl, CEO of FACT, serves on the Steering Committee. FACT sets accreditation standards for cellular therapy treatment centers.
- International Myeloma Foundation (IMF)supportingIMF has endorsed the CAR T Vision. Yelak Biru, Immediate Past-President and CEO of IMF, serves on the Steering Committee. IMF focuses on patient education, clinical trials, and access disparities in myeloma.
- Leukemia & Lymphoma Society (LLS)supportingLLS has endorsed the CAR T Vision, supporting advocacy efforts to improve access to CAR T-cell therapy for blood cancer patients.
- Lymphoma CoalitionsupportingLymphoma Coalition has endorsed the CAR T Vision. Lorna Warwick, CEO of Lymphoma Coalition, serves on the Steering Committee. The coalition is a global network supporting lymphoma patients.
- American Society for Transplantation and Cellular Therapy (ASTCT)coreASTCT is a key institutional partner. ASTCT and ACCC co-launched the RECUR initiative in 2024. ASTCT also launched the 80/20 Initiative to streamline onboarding for CAR T treatment centers. Miguel-Angel Perales (Co-Chair of CAR T Vision) is Past-President of ASTCT.
- Spanish Ministry of Health / IDEaL Project Partners (SEHH, GELTAMO, GETH-TC)supportingThe IDEaL project (Identificación y Derivación Temprana de Pacientes con Linfoma Candidatos a Terapias CAR-T) was launched in 2024 with three Spanish professional societies — SEHH, GELTAMO, and GETH-TC — and funded by Gilead and Kite, to improve early identification and referral for CAR T-cell therapy in Spain.
- National Marrow Donor Program (NMDP) / Be The MatchcoreNMDP and ASTCT co-created the ACCESS Initiative in 2022 to reduce disparities in access to cell therapy and HCT in the US, addressing barriers related to race, poverty, and geography.
- GoCART Coalition (European Hematology Association and EBMT)coreThe GoCART Coalition was founded in 2020 by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT). It is a multi-stakeholder coalition working to promote patient access to cellular therapies in Europe. Dr. Michael Hudecek from CAR T Vision Steering Committee serves as project coordinator of the T2EVOLVE IMI Consortium linked to the GoCART Coalition.
Scale indicators5 records
Recent moves5 records
Expansion highlights4 records
CAR T Vision competitors and assessment
Company assessmentOthers
- National Organization for Rare Disorders (NORD): US-based patient advocacy organization driving rare-disease policy, reimbursement, and access reform. Comparable in operating a multi-stakeholder advocacy model focused on expanding treatment access, though broader than CAR-T specifically.
Broad incumbents
- European Cancer Organisation (ECCO): Multi-stakeholder European cancer policy organization convening clinicians, researchers, and patient advocates to influence EU cancer policy. Comparable in operating model (multi-stakeholder coalition driving policy change in oncology) but broader in scope than CAR-T.
- Cell and Gene Therapy Catapult (CGT Catapult): UK-established organization accelerating cell and gene therapy development and adoption, including the ATTC network. Comparable in advancing cell-therapy access infrastructure; differs in being a state-backed delivery body rather than an advocacy coalition.
Direct peers
- Friends of Cancer Research: US-based cancer research and policy advocacy coalition that brings together patients, researchers, regulators, and industry to drive legislative and regulatory change. Closely comparable multi-stakeholder advocacy coalition model applied to oncology access.
- GoCART Coalition: Multi-stakeholder coalition founded in 2020 by the European Hematology Association (EHA) and EBMT to promote patient access to cellular therapies in Europe. The most structurally comparable coalition to CAR T Vision, operating in the same CAR-T/cell therapy access space with overlapping steering-committee membership (Dr. Hudecek coordinates T2EVOLVE linked to GoCART).
- Lymphoma Coalition: Global network of lymphoma patient organizations focused on access, awareness, and advocacy. Comparable as a coalition-style access-advocacy organization; also serves as an endorsing partner of CAR T Vision.
- Multiple Myeloma Research Foundation (MMRF): Disease-specific patient advocacy and research organization that drives access, clinical trial enrollment, and policy advocacy for multiple myeloma patients — directly overlapping with CAR T Vision's myeloma patient segment and access mission.
- All.Can International: International multi-stakeholder initiative focused on improving efficiency in cancer care across Europe. Comparable as a multi-stakeholder advocacy coalition model with industry, clinician, and patient representation and measurable improvement goals.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
CAR T Vision social profiles
Digital presenceCAR T Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
CAR T Vision leadership team
Management profileNumber of profiles
Profiles16 records
CAR T Vision funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CAR T Vision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CAR T Vision
What does CAR T Vision do?
CAR T Vision is an independent healthcare advocacy coalition that publishes expert-informed reports, blueprints, toolkits, and case studies to drive stakeholder action on expanding patient access to CAR T-cell therapy. It is led by a multidisciplinary global Steering Committee and operates without selling any commercial products; all publications are distributed for free via its website to align policymakers, payors, healthcare professionals, patient advocates, and industry around the goal of doubling the proportion of eligible patients treated by 2030.
Is CAR T Vision a public or private company?
CAR T Vision is a private company. It is classified as unknown and is currently operating.
When was CAR T Vision founded?
CAR T Vision was founded in 2025. It employs 1 to 10 people.
Where is CAR T Vision based?
CAR T Vision is headquartered in London, United Kingdom, in the Europe region.
How does CAR T Vision make money?
One revenue line is on record: industry funding and support.
Who are CAR T Vision's main competitors?
National Organization for Rare Disorders (NORD) is listed as an others. Broad incumbents are European Cancer Organisation (ECCO) and Cell and Gene Therapy Catapult (CGT Catapult). Direct peers are Friends of Cancer Research, GoCART Coalition, Lymphoma Coalition, Multiple Myeloma Research Foundation (MMRF) and All.Can International.
Does CAR T Vision have an API?
No public API is recorded for CAR T Vision.
What industry is CAR T Vision in?
CAR T Vision's product category is Healthcare Advocacy Coalition Publications. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies. Its SIC code is 8000.